Salivary gland cancer — epidemiology

Kordzińska-Cisek, Izabela; Grzybowska‐Szatkowska, Ludmiła

doi:10.5603/njo.2018.0005

Cited by 20 publications

(25 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of patients with individual histological types differs from their prevalence in the whole population. 16 This is due to the fact that patients with particularly prognostically bad histopathological types were qualified for radiotherapy. For instance, squamous cell carcinoma accounts for only 6-14% of salivary gland cancers in the general population.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

<p>The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy – A Single Institution Experience</p>

Kordzińska-Cisek

Cisek

Grzybowska‐Szatkowska

2020

CMAR

Self Cite

View full text Add to dashboard Cite

Purpose: Salivary gland neoplasms are rare cancers of the head and neck region. Radical treatment in tumors of large salivary glands is surgery. Adjuvant treatment depends on the presence of risk factors that worsen the prognosis, but the role of these factors in patients treated by surgery with radio-or radiochemotherapy still remains unclear. The aim of the study is assessment of treatment results and identification of the risk factors affecting the prognosis in patients with tumors of large salivary glands subjected to adjuvant radio-or radiochemotherapy. Patients and Methods: The study included 126 patients with local stage large salivary gland cancer who were treated surgically with adjuvant radio-or radiochemotherapy. The study excluded inoperable patients, patients with distant metastases, patients in a poor general condition and patients with contraindications to adjuvant treatment. They were treated between 2006 and 2016 and evaluated in terms of OS (overall survival), CSS (cancer-specific survival), RFS (relapse-free survival) and LRFS (local relapse-free survival). Results: During a 44-month follow-up, 5-OS, CSS, RFS and LRFS were 55%, 68%, 60% and 73%, respectively. Multivariate analysis showed that OS was influenced by the following parameters: WHO performance status, TNM stage (T and N parameters), radicality of surgery, histopathological type, applied method of radiotherapy planning and tumor volume. WHO performance status, T and N parameters of the TNM stage and large volume of elective area influenced CSS, and the T parameter of the TNM stage, the dose below 60Gy and tumor volume influenced RFS and LRFS. Chemoradiotherapy can be used in N-positive patients. Conclusion: The analysis indicates that the TNM grade, histopathological type, patient's condition, radicality of the procedure, technique and dose of radiotherapy are the most important prognostic factors in these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

“…For instance, squamous cell carcinoma accounts for only 6-14% of salivary gland cancers in the general population. 16 It is also the type that had the statistically worst impact on overall survival. This is confirmed by the literature data.…”

Section: Discussionmentioning

confidence: 99%

<p>The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy – A Single Institution Experience</p>

Kordzińska-Cisek

Cisek

Grzybowska‐Szatkowska

2020

CMAR

Self Cite

View full text Add to dashboard Cite

show abstract

“…Salivary duct carcinoma 0.05-2/100,000 [94] • Molecular characterisation of salivary duct carcinoma using proteomics and genomics [95] Sarcoma 0.1-5/100,000 [96] • Molecular characterisation of cancers by TCGA across tissues of origin [43,49] • Identification of novel therapeutic targets through multi-omic analysis [97].…”

Section: Rare Renal Cancers (Chrcc O Tlfrcc P )mentioning

confidence: 99%

A scoping review and proposed workflow for multi-omic rare disease research

Kerr¹,

McAneney²,

Smyth³

et al. 2020

Orphanet J Rare Dis

View full text Add to dashboard Cite

Background: Patients with rare diseases face unique challenges in obtaining a diagnosis, appropriate medical care and access to support services. Whole genome and exome sequencing have increased identification of causal variants compared to single gene testing alone, with diagnostic rates of approximately 50% for inherited diseases, however integrated multi-omic analysis may further increase diagnostic yield. Additionally, multi-omic analysis can aid the explanation of genotypic and phenotypic heterogeneity, which may not be evident from single omic analyses. Main body: This scoping review took a systematic approach to comprehensively search the electronic databases MEDLINE, EMBASE, PubMed, Web of Science, Scopus, Google Scholar, and the grey literature databases OpenGrey / GreyLit for journal articles pertaining to multi-omics and rare disease, written in English and published prior to the 30th December 2018. Additionally, The Cancer Genome Atlas publications were searched for relevant studies and forward citation searching / screening of reference lists was performed to identify further eligible articles. Following title, abstract and full text screening, 66 articles were found to be eligible for inclusion in this review. Of these 42 (64%) were studies of multi-omics and rare cancer, two (3%) were studies of multi-omics and a pre-cancerous condition, and 22 (33.3%) were studies of non-cancerous rare diseases. The average age of participants (where known) across studies was 39.4 years. There has been a significant increase in the number of multi-omic studies in recent years, with 66.7% of included studies conducted since 2016 and 33% since 2018. Fourteen combinations of multi-omic analyses for rare disease research were returned spanning genomics, epigenomics, transcriptomics, proteomics, phenomics and metabolomics. Conclusions: This scoping review emphasises the value of multi-omic analysis for rare disease research in several ways compared to single omic analysis, ranging from the provision of a diagnosis, identification of prognostic biomarkers, distinct molecular subtypes (particularly for rare cancers), and identification of novel therapeutic targets. Moving forward there is a critical need for collaboration of multi-omic rare disease studies to increase the potential to generate robust outcomes and development of standardised biorepository collection and reporting structures for multi-omic studies.

show abstract

“…Unfortunately, a number of inflammatory and reactive lesions of the salivary glands may mimic neoplastic disease, so in most patients, imaging diagnosis, including ultrasonography and magnetic resonance imaging or computed tomography, must be routinely performed. Salivary gland tumors account for 3 to 10% of all head and neck cancers [ 1 , 2 , 3 , 4 ]; in Europe, this percentage is 8.5% [ 5 ]. Most of the proliferative lesions in the salivary glands are benign, and only less than 20% are malignant [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

The Epidemiology of Salivary Glands Pathologies in Adult Population over 10 Years in Poland—Cohort Study

Žůrek

Rzepakowska

Jasak

et al. 2021

IJERPH

View full text Add to dashboard Cite

Background: The aim of this study was a comprehensive analysis of the incidence of different salivary gland pathologies in the adult population of Poland. Methods: A retrospective analysis of salivary gland pathologies diagnosed in Poland in 2010–2019 based on the National Health Fund (NHF) database was performed. Non-neoplastic diseases, and benign and malignant lesions were identified using ICD-10 codes. Demographic characteristics, incidence rates, and the number of inpatient and outpatient medical services were analyzed. Results: Salivary gland pathologies were diagnosed in 230,589 patients over 10 years (85.5% were non-neoplastic lesions, 11.53% benign and 2.93% malignant neoplasms). Incidence rate for all pathologies was 59.94/100,000. The mean incidence for malignant neoplasms was 1.78, and decreasing trend was observed over the analyzed period. Contrarily, for benign neoplasms (mean incidence—6.91), an increase in numbers was noted annually. The incidence for non-malignant lesions was quite stable (mean: 51.25) over the time. The highest number of medical services per patient concerned malignant neoplasms (on average, two hospital stays, and eleven outpatient consultations). Conclusions: An increase of benign salivary gland tumors, and a decrease of malignant neoplasms was observed during the studied period. The number of medical services related to salivary gland pathologies increased during the period under study.

show abstract

Salivary gland cancer — epidemiology

Cited by 20 publications

References 21 publications

<p>The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy – A Single Institution Experience</p>

<p>The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy – A Single Institution Experience</p>

A scoping review and proposed workflow for multi-omic rare disease research

The Epidemiology of Salivary Glands Pathologies in Adult Population over 10 Years in Poland—Cohort Study

Contact Info

Product

Resources

About